Stockscreener 앱 받기
0.8371
10.00%
-0.1332
시간 외 거래:
.86
0.023
+2.74%
전일 마감가:
$0.9702
열려 있는:
$1
하루 거래량:
255.50K
Relative Volume:
6.78
시가총액:
$36.05M
수익:
$13.42M
순이익/손실:
$-73.35M
주가수익비율:
-
EPS:
-
순현금흐름:
$-56.34M
1주 성능:
-36.42%
1개월 성능:
-29.01%
6개월 성능:
-62.84%
1년 성능:
-68.25%
1일 변동 폭
$0.81
$1.00
1주일 범위
$0.81
$1.44
52주 변동 폭
$0.81
$4.1591
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
명칭
Barinthus Biotherapeutics Plc Adr
전화
44 (0) 1865 818808
주소
UNIT 6-10, ZEUS BUILDING, DIDCOT
BRNS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BRNS | 0.8371 | 36.05M | 13.42M | -73.35M | -56.34M | 0.00 |
| VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Barinthus Biotherapeutics Plc Adr 주식(BRNS)의 최신 뉴스
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ... - Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket By ... - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Barinthus Bio refocuses on hepatitis B and celiac disease treatments By Investing.com - Investing.com
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewswire Inc.
Market Update: Barinthus Biotherapeutics Plc. ADR (BRNS) Sees Negative Movement, Closing at 2.00 – DWinneX - The Dwinnex
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 - Investing.com India
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments - Investing.com India
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates - Zacks Investment Research
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
ANVS Stock Quote Price and Forecast - CNN
TPST Stock Quote Price and Forecast - CNN
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Barinthus Biotherapeutics Plc Adr (BRNS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.27%
0.88%
자본화:
|
볼륨(24시간):